Evidence map›Paper›PMID 30964528›Full record

ArticleJAMA2019

Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.

Michael W Traeger, Vincent J Cornelisse, Jason Asselin, Brian Price, Norman J Roth, Jeff Willcox, Ban Kiem Tee, Christopher K Fairley, Christina C Chang, Jude Armishaw and 22 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in JAMA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06860945 (Development of a Predictive Model for Sexually Transmitted Infections in Individuals Using Pre-Exposure Prophylaxis for HIV in Spain), which is not on this map. Cited by 187 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
187citing papers in PubMed, 5 pooled it
32.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06860945 recruitingnot on this mapstarted 2025, after this paper: background citation

Development of a Predictive Model for Sexually Transmitted Infections in Individuals Using Pre-Exposure Prophylaxis for HIV in Spain

Typeobservational_patient_registrySponsorHospital Universitario de ValmeRan2025 to 2026Enrolled9,000ConditionsSexually Transmitted Infections (STIs), HIV, PrEPArmsNo Intervention: Observational Cohort
3 · Its place in the literature

Who cites it

187 citing papers in PubMed, 5 syntheses or guidelines pooled it, 392 citations in OpenAlex.

  1. Pooled it
  2. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2024
    Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Resistance-Guided Treatment of Gonorrhea: A Prospective Clinical Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

127 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 8 institutions in 1 country.

Michael W TraegerDisease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
Vincent J CornelisseDepartment of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia.
Jason AsselinDisease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
Brian PriceDepartment of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia.
Norman J RothPrahran Market Clinic, Melbourne, Victoria, Australia.
Jeff WillcoxNorthside Clinic, Melbourne, Victoria, Australia.
Ban Kiem TeeCentre Clinic, Thorne Harbour Health, Melbourne, Victoria, Australia.
Christopher K FairleyMelbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.
Christina C ChangDepartment of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia.
Jude ArmishawDepartment of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia.
Olga VujovicDepartment of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia.
Matthew PennPRONTO! Clinic, Thorne Harbour Health, Melbourne, Victoria, Australia.
Pauline CundillPRONTO! Clinic, Thorne Harbour Health, Melbourne, Victoria, Australia.
George Forgan-SmithERA Health, Melbourne, Victoria, Australia.
John GallERA Health, Melbourne, Victoria, Australia.
Claire PickettBallarat Community Health Centre, Ballarat, Victoria, Australia.
Luxi LalDisease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
Anne MakDepartment of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia.
Tim D SpelmanDisease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
Long NguyenDisease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
Dean A MurphyDepartment of Gender and Cultural Studies, University of Sydney, Sydney, New South Wales, Australia.
Kathleen E RyanDisease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
Carol El-HayekDisease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
Michael WestSexual Health and Viral Hepatitis Service, Department of Health and Human Services, Government of Victoria, Melbourne, Victoria, Australia.
Simon RuthThorne Harbour Health, Melbourne, Victoria, Australia.
Colin BatrouneyThorne Harbour Health, Melbourne, Victoria, Australia.
John T LockwoodDepartment of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia.
Jennifer F HoyDepartment of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia.
Margaret E HellardDisease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
Mark A StoovéDisease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
Edwina J WrightDisease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
PrEPX Study Team
Burnet Institute · AUMonash University · AUAlfred Health · AUMelbourne Clinic · AUBallarat Health Services · AUDepartment of Health and Human Services · AUUniversity of Melbourne · AUUniversity of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Emerging evidence suggests that risk of bacterial sexually transmitted infections (STIs) increases among gay and bisexual men following initiation of HIV preexposure prophylaxis (PrEP). Objective: To describe STI incidence and behavioral risk factors among a cohort of predominantly gay and bisexual men who use PrEP, and to explore changes in STI incidence following PrEP commencement. Design, Setting, and Participants: The Pre-exposure Prophylaxis Expanded (PrEPX) Study, a multisite, open-label intervention study, was nested within the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS) clinic network. A total of 4275 participants were enrolled (July 26, 2016-April 1, 2018) in Victoria, Australia. Of these, 2981 enrolled at 5 ACCESS clinics (3 primary care, 1 sexual health, and 1 community-based HIV rapid testing service), had at least 1 follow-up visit, and were monitored until April 30, 2018. Exposures: Upon enrollment, participants received daily oral tenofovir disoproxil fumurate and emtricitabine for HIV PrEP, quarterly HIV and STI testing, and clinical monitoring. Main Outcomes and Measures: The primary outcome was incidence of chlamydia, gonorrhea, or syphilis. Incidence rates and hazard ratios describing behavioral risk factors of STI diagnosis were calculated. Incidence rate ratios (IRRs), adjusted for change in testing frequency, described changes in STI incidence from 1-year preenrollment to study follow-up among participants with preenrollment testing data (n = 1378). Results: Among the 2981 individuals (median age, 34 years [interquartile range, 28-42]), 98.5% identified as gay or bisexual males, 29% used PrEP prior to enrollment, 89 (3%) withdrew and were censored at date of withdrawal, leaving 2892 (97.0%) enrolled at final follow-up. During a mean follow-up of 1.1 years (3185.0 person-years), 2928 STIs were diagnosed among 1427 (48%) participants (1434 chlamydia, 1242 gonorrhea, 252 syphilis). STI incidence was 91.9 per 100 person-years, with 736 participants (25%) accounting for 2237 (76%) of all STIs. Among 2058 participants with complete data for multivariable analysis, younger age, greater partner number, and group sex were associated with greater STI risk, but condom use was not. Among 1378 participants with preenrollment testing data, STI incidence increased from 69.5 per 100 person-years prior to enrollment to 98.4 per 100 person-years during follow-up (IRR, 1.41 [95% CI, 1.29-1.56]). After adjusting for testing frequency, the increase in incidence from 1 year preenrollment to follow-up was significant for any STI (adjusted IRR, 1.12 [95% CI, 1.02-1.23]) and for chlamydia (adjusted IRR, 1.17 [95% CI, 1.04-1.33]). Conclusions and Relevance: Among gay and bisexual men using PrEP, STIs were highly concentrated among a subset, and receipt of PrEP after study enrollment was associated with an increased incidence of STIs compared with preenrollment. These findings highlight the importance of frequent STI testing among gay and bisexual men using PrEP.

Indexed as

BisexualityHomosexuality, MalePre-Exposure ProphylaxisAdolescentAdultAnti-HIV AgentsAustraliaDrug Therapy, CombinationEmtricitabineHIV InfectionsHumansIncidenceMaleMiddle AgedPopulation SurveillanceProportional Hazards ModelsAnti-HIV AgentsEmtricitabineTenofovir

Identifiers

PMID30964528
PMCPMC6459111
OpenAlexW2939720189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.